Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1996-09-11
1998-06-23
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
4241411, 4241501, 4241831, 4242431, 424 931, 424 9342, 4241651, 5303881, 5303882, 5303884, 5303895, 530402, 530403, 5361231, 514 54, A61K 39085, A61K 3940, C07K 1612
Patent
active
057702080
ABSTRACT:
A negatively-charged S. aureus antigen contains .beta.-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection.
REFERENCES:
patent: 4748020 (1988-05-01), von Malsen-Ponickau
patent: 5032522 (1991-07-01), Watson
Karakawa et al., "Method for the Serological Typing of the Capsular Polysaccharides of Staphylococcus aureus,", Journal of Clinical Microbiology, vol. 22, Sep., 1985, pp. 445-447.
Fattom et al., "A Staphylococcus aureus Capsular Polysaccharide (CP) Vaccine and CP-specific Antibodies Protect Mice Against Bacterial Challenge," Infection and Immunity, vol. 64, No. 5, May 1996, pp. 1659-1665).
Fattom et al., "Laboratory and Clinical Evaluation of Conjugate Vaccines Composed of Staphylococcus aureus Type 5 and Type 8 Capsular Polysaccharides Bound to Pseudomonas aeruginoas Recombinant Exoprotein A," Infection and Immunity, vol. 61, Mar. 1993.
T.A. Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy," Science, vol. 252, Jun. 21, 1991, pp. 1657-1662.
Roitt et al, "Immunotherapy," in Immunology, Fourth Edition, 1996, pp. 20.0-20.10.
Davison et al., "Teichoic Acids in the Walls of Staphylococci: Serological Investigation on Teichoic Acids from the Walls of Staphylococci" Nature, vol. 202, May 30, 1964, pp. 872-874.
Endl et al., "Chemical Composition and Structure of Cell Wall Teichoic Acids of Staphylococci" Archives of Microbiology, 135:215-223, 1983.
Rajbhandary et al., "The Intracellular Teichoic Acid from Staphylococcus aureus H" Biochem J. 87:429-435 (1963).
Anthony, et al. Gram Positive Bacteria: An Overview and Summary of Session Reviews of Infectious Diseases, 10:2 S345-S350 (1988).
Foster Potential for vaccination against infections caused by Staphylococcus aureus, Vaccine 9:221-227.
Fattom Synthesis and Immunologic Properties in Mice of Vaccines Composed of Staphylococcus aureus Type 5 and Type 8 Capsular Polysaccharides Conjugated to Pseudomonas aeruginose Exotoxin A Infection and Immunity 58:7 2367-2374 (1990).
Fattom A Staphylococcus aureus Capsular Polysaccharide (CP) Vaccine and CP-Specific Antibodies Protect Mice against Bacterial Challenge, Infection and Immunity 64:5 1659-1665 (1996).
Fournier Purification and Characterization of Staphylococcus aureus Type 8 Capsular Polysaccharide Infection and Immunity, 45:1 87-93 (1984).
Karakawa Method for the Serological Typing of the Capsular Polysaccharides of Staphylococcus aureus, Journal of Clinical Microbiology 22:3 445-447 (1985).
Moreau Structure of the type 5 capsular polysaccharide of Staphylococcus aureus Carbohydrate Research, 201:285-297 (1990).
Fattom Ali Ibrahim
Patel Atulkumar Induprasad
Caputa Anthony C.
Nabi
LandOfFree
Staphylococcus aureus B-linked hexosamine antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Staphylococcus aureus B-linked hexosamine antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Staphylococcus aureus B-linked hexosamine antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1392546